erlotinib hydrochloride has been researched along with Corneal Perforation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mangan, MS | 1 |
| Molina, JJ; Molina-Prat, N; Morral, M; Quintana, R; Saint-Jean, A; Sainz de la Maza, M; Torras, J | 1 |
2 other study(ies) available for erlotinib hydrochloride and Corneal Perforation
| Article | Year |
|---|---|
Dramatic Improvement of Severe Cicatricial Ectropion after Discontinuing Long-Term Erlotinib Therapy in a Patient with Lung Cancer
Topics: Carcinoma, Non-Small-Cell Lung; Corneal Perforation; Ectropion; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Toxic Optic Neuropathy | 2022 |
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Corneal Perforation; Ectropion; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratoplasty, Penetrating; Lung Neoplasms; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Visual Acuity | 2012 |